LIfT BioSciences granted €12M from Ireland’s Disruptive Technologies Innovation Fund to support the first-in-human clinical trial of LIfT’s IMAN therapy

Alex Blyth, Chief Executive Officer of LIfT Biosciences, said: “The grant awarded from DTIF is a significant milestone for LIfT as we expand our presence in Ireland and advance toward closing the second round of our Series A financing. By combining LIfT’s innovative immunotherapy platform with the University of Galway’s deep expertise in oncology, patient care, and advanced manufacturing, and Hooke Bio’s analytical expertise, we are enhancing our clinical-stage research and accelerating the path to delivering IMANs to patients. The majority of this grant will support CMC manufacturing and the clinical trial itself, positioning LIfT at the forefront of next-generation cancer immunotherapies.”

Share:

More News

Taiho Oncology, Inc. completed a New Drug Application (NDA) submission to the U.S. Food and Drug Administration (FDA) for zipalertinib in combination with platinum-based chemotherapy for the treatment of patients with previously untreated, locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) exon 20

“This collaboration reflects our conviction that atebimetinib has the potential to become an essential backbone therapy in a broad range of combinations across MAPK-driven cancers,” said Ben Zeskind, Immuneering CEO and co-founder. “Atebimetinib’s unique tolerability profile and broad activity make it well suited to combine with a wide range of

“These final updated results provide continued evidence of the potential for γδ T cell therapies to drive activity and improve outcomes for patients,” said William Ho, CEO and co-founder of IN8bio. “The clinical outcomes and observed activity are supported by our correlative analysis, including histopathology, demonstrating the expansion and persistence

“Patients with RAS-mutated mCRC have no first-line therapies specifically approved for their disease, and Fast Track designation reflects the potential of onvansertib to address this serious unmet need,” said Mani Mohindru, PhD, President and Chief Executive Officer of Cardiff Oncology. “Our randomized Phase 2 data give us confidence that onvansertib